Skip to main content
Monday, November 16, 2026Nov 16

US to rein in flood of coronavirus blood tests after lax oversight

FILE - In this April 14, 2020 file photo, a woman holds her hand out to have blood collected for COVID-19 antibodies at a drive-thru site in Hempstead, N.Y. U.S. regulators on Monday, May 4 pulled back a decision that allowed scores of coronavirus blood tests to hit the market without first providing proof that they worked. The Food and Drug Administration said it took the action because some sellers have made false claims about the tests and their accuracy. (AP Photo/Seth Wenig, File)
FILE - In this April 14, 2020 file photo, a woman holds her hand out to have blood collected for COVID-19 antibodies at a drive-thru site in Hempstead, N.Y. U.S. regulators on Monday, May 4 pulled back a decision that allowed scores of coronavirus blood tests to hit the market without first providing proof that they worked. The Food and Drug Administration said it took the action because some sellers have made false claims about the tests and their accuracy. (AP Photo/Seth Wenig, File)

WASHINGTON (AP) – U.S. regulators Monday pulled back a decision that allowed scores of coronavirus blood tests to hit the market without first providing proof that they worked.

The Food and Drug Administration said it took the action because some sellers have made false claims about the tests and their accuracy. Companies will now have to show their tests work or risk having them pulled from the market.

Under pressure to increase testing options, the FDA in March essentially allowed companies to begin selling tests as long as they notified the agency of their plans and provided disclaimers, including that they were not FDA approved. The policy was intended to allow “flexibility” needed to quickly ramp up production, officials said.

“However, flexibility never meant we would allow fraud,” Dr. Anand Shah, an FDA deputy commissioner, said in a statement. “We unfortunately see unscrupulous actors marketing fraudulent test kits and using the pandemic as an opportunity to take advantage of Americans.”

Blood tests are different from the nasal swab tests currently used to diagnose active COVID-19 infections. Instead, the tests look for blood proteins called antibodies, which the body produces days or weeks after fighting an infection. Most use a finger-prick of blood on a test strip.